Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Radiotherapy

Neurocognitive considerations in the treatment of brain metastases

Nature Reviews Clinical Oncology volume 7, pages 185–186 (2010)Cite this article

Subjects

The results of a randomized, controlled trial investigating the neurocognitive effects of stereotactic radiosurgery (SRS), with or without whole-brain radiation therapy (WBRT), to treat brain metastases demonstrated a significant reduction in learning and memory, associated with the addition of WBRT to SRS. The results indicate that SRS monotherapy is an effective and safe initial management strategy for brain metastases.

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Brown, P. D., Asher, A. L. & Farace, E. Adjuvant whole brain radiotherapy: strong emotions decide but rational studies are needed. Int. J. Radiat. Oncol. Biol. Phys. 70, 1305–1309 (2008).

    Article  PubMed  Google Scholar 

  2. Meyers, C. A. & Brown, P. D. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J. Clin. Oncol. 24, 1305–1309 (2006).

    Article  PubMed  Google Scholar 

  3. Chang, E. L. et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 10, 1037–1044 (2009).

    Article  PubMed  Google Scholar 

  4. Patchell, R. A. et al. A randomized trial of surgery in the treatment of single metastases to the brain. N. Engl. J. Med. 322, 494–500 (1990).

    Article  CAS  PubMed  Google Scholar 

  5. Aoyama, H. et al. Neurocognitive function of patients with brain metastasis who received either whole brain radiotherapy plus stereotactic radiosurgery or radiosurgery alone. Int. J. Radiat. Oncol. Biol. Phys. 68, 1388–1395 (2007).

    Article  PubMed  Google Scholar 

  6. Regine, W. F. et al. Risk of symptomatic brain tumor recurrence and neurologic deficit after radiosurgery alone in patients with newly diagnosed brain metastases: results and implications. Int. J. Radiat. Oncol. Biol. Phys. 52, 333–338 (2002).

    Article  PubMed  Google Scholar 

  7. Andrews, D. W. et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 363, 1665–1672 (2004).

    Article  PubMed  Google Scholar 

  8. Regine, W. F., Scott, C., Murray, K. & Curran, W. Neurocognitive outcome in brain metastases patients treated with accelerated-fractionation vs. accelerated-hyperfractionated radiotherapy: an analysis from Radiation Therapy Oncology Group Study 91–04. Int. J. Radiat. Oncol. Biol. Phys. 51, 711–717 (2001).

    Article  CAS  PubMed  Google Scholar 

  9. Sneed, P. K. et al. A multi-institutional review of radiosurgery alone vs. radiosurgery with whole brain radiotherapy as the initial management of brain metastases. Int. J. Radiat. Oncol. Biol. Phys. 53, 519–526 (2002).

    Article  PubMed  Google Scholar 

  10. Aoyama, H. et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 295, 2483–2491 (2006).

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This research was supported in part by Grant W81XWH-062-0033 from the US Department of Defense Breast Cancer Research Program to R. J. Weil. We wish to thank the M. Burkhardt, Chair in neurosurgical oncology and the Karen Colina Wilson research endowment within the Brain Tumor and Neuro-oncology Center at the Cleveland Clinic Foundation for additional support and funding.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The Brain Tumor and Neuro-Oncology Center, Cleveland Clinic, ND-40, 9500 Euclid Avenue, Cleveland, 44195, OH, USA

    Nicholas F. Marko & Robert J. Weil

Authors
  1. Nicholas F. Marko
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Robert J. Weil
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Nicholas F. Marko.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Marko, N., Weil, R. Neurocognitive considerations in the treatment of brain metastases. Nat Rev Clin Oncol 7, 185–186 (2010). https://doi.org/10.1038/nrclinonc.2010.30

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrclinonc.2010.30

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer